Viracta Therapeutics Inc.
0.16
-0.01 (-5.83%)
At close: Jan 15, 2025, 2:44 PM
undefined%
Bid 0.16
Market Cap 6.55M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.1
PE Ratio (ttm) -0.15
Forward PE n/a
Analyst Buy
Ask 0.17
Volume 618,497
Avg. Volume (20D) 2,875,839
Open 0.18
Previous Close 0.17
Day's Range 0.15 - 0.18
52-Week Range 0.13 - 1.31
Beta undefined

About VIRX

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as we...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2005
Employees 40
Stock Exchange NASDAQ
Ticker Symbol VIRX

Analyst Forecast

According to 4 analyst ratings, the average rating for VIRX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 1719.28% from the latest price.

Buy 75.00%
Hold 25.00%
Sell 0.00%
Stock Forecasts
5 months ago · Source
-11.76%
Viracta Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
9 months ago · Source
-32.17%
Viracta Therapeutics shares are trading lower. The company announced topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma cohort.